Go Pro
NASDAQ:BTCY

Biotricity Q4 2026 Earnings Report

Biotricity logo
$0.13 +0.01 (+4.34%)
As of 07/10/2026 12:11 PM Eastern

Biotricity EPS Results

Actual EPS
N/A
Consensus EPS
-$0.08
Beat/Miss
N/A
One Year Ago EPS
N/A

Biotricity Revenue Results

Actual Revenue
N/A
Expected Revenue
$4.10 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biotricity Announcement Details

Quarter
Q4 2026
Time
N/A
Conference Call Date
Friday, July 17, 2026
Conference Call Time
4:00PM ET

Conference Call Resources

Biotricity Earnings Headlines

Biotricity Q3 2026 Earnings Call: Complete Transcript
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel
Biotricity, Inc. (BTCY) Q3 2026 Earnings Call Transcript
See More Biotricity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biotricity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biotricity and other key companies, straight to your email.

About Biotricity

Biotricity (NASDAQ:BTCY) (NASDAQ:BTCY) is a digital health company specializing in remote patient monitoring solutions across cardiovascular and chronic disease management. The firm develops and commercializes a patented wearable biosensor platform designed to capture continuous physiological data, including electrocardiogram (ECG) readings and heart rate variability. This integrated system combines lightweight, adhesive biosensors with cloud-based analytics and clinician-facing software to support early detection of cardiac arrhythmias and facilitate telehealth care delivery.

The company’s flagship offering, the Bioflux™ platform, comprises a small, single-use wearable device that transmits real-time data to a secure portal, where advanced algorithms analyze cardiac patterns and generate clinician alerts. Complementing the hardware are subscription-based services—such as Bioflux™ Rx—through which Biotricity provides end-to-end monitoring programs under a prescription model. These programs enable cardiologists, primary care physicians, and remote monitoring centers to review patient data remotely, optimize treatment plans and enhance patient engagement without the need for in-office visits.

Founded in 2015 and headquartered in Menlo Park, California, Biotricity serves healthcare providers and payors throughout the United States, with emerging international partnerships aimed at expanding telemedicine adoption. Under the leadership of Founder and Chief Executive Officer Amir Kalali, the company has secured regulatory clearances for multiple product lines and continues to invest in research and development to broaden its digital health ecosystem. Biotricity’s solutions target efficient, patient-centric care by leveraging real-world data and scalable technology to address growing demands for remote monitoring in modern healthcare.

View Biotricity Profile